≤2cm乳腺癌患者超声征象及其与分子生物表达的相关性研究

Ultrasound Signs of Patients with ≤2cm Breast Cancer and Their Correlation with Molecular Biological Expression

目的探究≤2cm乳腺癌患者超声征象及其与分子生物表达的相关性。方法回顾性分析2017年1月~2018年12月本院诊治的65例乳腺癌患者临床资料,飞利浦IU22彩色多普勒超声检测仪检测乳腺癌病灶部位、大小、形态、是否有毛刺、内部回声等情况,免疫组织化学法染色乳腺癌组织标本中雌激素受体(ER)、孕激素受体(PR)、原癌基因(CerB2)表达情况。结果直径≤2cm的乳腺癌患者超声征象以边缘毛刺征(58.46%)、微小钙化灶(61.54%)最为常见,乳腺癌患者边缘毛刺征、微小钙化灶与ER、PR阳性表达率明显相关,边缘高回声晕征与CerB2阳性表达率有关(P<0.05)。结论≤2cm乳腺癌患者超声征象与其分子生物学指标密切相关,有毛刺征及微小钙化灶征象乳腺癌有更高ER、PR阳性表达率,而边缘高回声晕征乳腺癌有更高CerB2阳性表达率,两者联合检测可为乳腺癌早期合理治疗方案选择及预后判断提供有用参考信息。

Objective Toexplore the ultrasound signs of patients with ≤2 cm breast cancer and their correlation with molecular biological expression. Methods The clinical data of 65 breast cancer patients diagnosed and treated in the hospital from January 2017 to December 2018 were retrospectively analyzed. The Philips IU22 color Doppler ultrasound detector was used to detect the location, size and shape of breast cancer lesions, presence or absence of burrs or internal echoes. Immunohistochemical staining was used to detect the expressions of estrogen receptor(ER), progesterone receptor(PR) and proto-oncogene(CerB2) in breast cancer tissue samples. Results Ultrasound signs of breast cancer patients with diameter ≤2 cm were most common with marginal burr signs(58.46%) and microcalcifications(61.54%). The marginal burr signs and microcalcifications of breast cancer patients were significantly correlated with the positive expression rates of ER and PR, and marginalhyperecho halo was associated with the positive expression rate of CerB2(P<0.05). Conclusion Ultrasound signs of patients with ≤2 cm breast cancer are closely related to their molecular biological indicators.Breast cancer patients with burr signs and microcalcifications have higherpositive expression rates of ER and PR, and breast cancer patients with marginal hyperecho halo has higher Cerb2 positive expression. The combination of the two methods can provide useful reference information for the rational selection of treatment regimens and prognosis judgement of early breast cancer.